Factor VIIa induces anti-inflammatory signaling via EPCR and PAR1
Recent studies show that endothelial cell protein C receptor (EPCR) interacts with diverse ligands, in addition to its known ligands protein C and activated protein C (APC). We showed in earlier studies that procoagulant clotting factor VIIa (FVIIa) binds EPCR and downregulates EPCR-mediated anticoa...
Saved in:
| Published in: | Blood Vol. 131; no. 21; p. 2379 |
|---|---|
| Main Authors: | , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
24.05.2018
|
| Subjects: | |
| ISSN: | 1528-0020, 1528-0020 |
| Online Access: | Get more information |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Recent studies show that endothelial cell protein C receptor (EPCR) interacts with diverse ligands, in addition to its known ligands protein C and activated protein C (APC). We showed in earlier studies that procoagulant clotting factor VIIa (FVIIa) binds EPCR and downregulates EPCR-mediated anticoagulation and induces an endothelial barrier protective effect. Here, we investigated the effect of FVIIa's interaction with EPCR on endothelial cell inflammation and lipopolysaccharide (LPS)-induced inflammatory responses in vivo. Treatment of endothelial cells with FVIIa suppressed tumor necrosis factor α (TNF-α)- and LPS-induced expression of cellular adhesion molecules and adherence of monocytes to endothelial cells. Inhibition of EPCR or protease-activated receptor 1 (PAR1) by either specific antibodies or small interfering RNA abolished the FVIIa-induced suppression of TNF-α- and LPS-induced expression of cellular adhesion molecules and interleukin-6. β-Arrestin-1 silencing blocked the FVIIa-induced anti-inflammatory effect in endothelial cells. In vivo studies showed that FVIIa treatment markedly suppressed LPS-induced inflammatory cytokines and infiltration of innate immune cells into the lung in wild-type and EPCR-overexpressing mice, but not in EPCR-deficient mice. Mechanistic studies revealed that FVIIa treatment inhibited TNF-α-induced ERK1/2, p38 MAPK, JNK, NF-κB, and C-Jun activation indicating that FVIIa-mediated signaling blocks an upstream signaling event in TNFα-induced signaling cascade. FVIIa treatment impaired the recruitment of TNF-receptor-associated factor 2 into the TNF receptor 1 signaling complex. Overall, our present data provide convincing evidence that FVIIa binding to EPCR elicits anti-inflammatory signaling via a PAR1- and β-arrestin-1 dependent pathway. The present study suggests new therapeutic potentials for FVIIa, which is currently in clinical use for treating bleeding disorders. |
|---|---|
| AbstractList | Recent studies show that endothelial cell protein C receptor (EPCR) interacts with diverse ligands, in addition to its known ligands protein C and activated protein C (APC). We showed in earlier studies that procoagulant clotting factor VIIa (FVIIa) binds EPCR and downregulates EPCR-mediated anticoagulation and induces an endothelial barrier protective effect. Here, we investigated the effect of FVIIa's interaction with EPCR on endothelial cell inflammation and lipopolysaccharide (LPS)-induced inflammatory responses in vivo. Treatment of endothelial cells with FVIIa suppressed tumor necrosis factor α (TNF-α)- and LPS-induced expression of cellular adhesion molecules and adherence of monocytes to endothelial cells. Inhibition of EPCR or protease-activated receptor 1 (PAR1) by either specific antibodies or small interfering RNA abolished the FVIIa-induced suppression of TNF-α- and LPS-induced expression of cellular adhesion molecules and interleukin-6. β-Arrestin-1 silencing blocked the FVIIa-induced anti-inflammatory effect in endothelial cells. In vivo studies showed that FVIIa treatment markedly suppressed LPS-induced inflammatory cytokines and infiltration of innate immune cells into the lung in wild-type and EPCR-overexpressing mice, but not in EPCR-deficient mice. Mechanistic studies revealed that FVIIa treatment inhibited TNF-α-induced ERK1/2, p38 MAPK, JNK, NF-κB, and C-Jun activation indicating that FVIIa-mediated signaling blocks an upstream signaling event in TNFα-induced signaling cascade. FVIIa treatment impaired the recruitment of TNF-receptor-associated factor 2 into the TNF receptor 1 signaling complex. Overall, our present data provide convincing evidence that FVIIa binding to EPCR elicits anti-inflammatory signaling via a PAR1- and β-arrestin-1 dependent pathway. The present study suggests new therapeutic potentials for FVIIa, which is currently in clinical use for treating bleeding disorders. Recent studies show that endothelial cell protein C receptor (EPCR) interacts with diverse ligands, in addition to its known ligands protein C and activated protein C (APC). We showed in earlier studies that procoagulant clotting factor VIIa (FVIIa) binds EPCR and downregulates EPCR-mediated anticoagulation and induces an endothelial barrier protective effect. Here, we investigated the effect of FVIIa's interaction with EPCR on endothelial cell inflammation and lipopolysaccharide (LPS)-induced inflammatory responses in vivo. Treatment of endothelial cells with FVIIa suppressed tumor necrosis factor α (TNF-α)- and LPS-induced expression of cellular adhesion molecules and adherence of monocytes to endothelial cells. Inhibition of EPCR or protease-activated receptor 1 (PAR1) by either specific antibodies or small interfering RNA abolished the FVIIa-induced suppression of TNF-α- and LPS-induced expression of cellular adhesion molecules and interleukin-6. β-Arrestin-1 silencing blocked the FVIIa-induced anti-inflammatory effect in endothelial cells. In vivo studies showed that FVIIa treatment markedly suppressed LPS-induced inflammatory cytokines and infiltration of innate immune cells into the lung in wild-type and EPCR-overexpressing mice, but not in EPCR-deficient mice. Mechanistic studies revealed that FVIIa treatment inhibited TNF-α-induced ERK1/2, p38 MAPK, JNK, NF-κB, and C-Jun activation indicating that FVIIa-mediated signaling blocks an upstream signaling event in TNFα-induced signaling cascade. FVIIa treatment impaired the recruitment of TNF-receptor-associated factor 2 into the TNF receptor 1 signaling complex. Overall, our present data provide convincing evidence that FVIIa binding to EPCR elicits anti-inflammatory signaling via a PAR1- and β-arrestin-1 dependent pathway. The present study suggests new therapeutic potentials for FVIIa, which is currently in clinical use for treating bleeding disorders.Recent studies show that endothelial cell protein C receptor (EPCR) interacts with diverse ligands, in addition to its known ligands protein C and activated protein C (APC). We showed in earlier studies that procoagulant clotting factor VIIa (FVIIa) binds EPCR and downregulates EPCR-mediated anticoagulation and induces an endothelial barrier protective effect. Here, we investigated the effect of FVIIa's interaction with EPCR on endothelial cell inflammation and lipopolysaccharide (LPS)-induced inflammatory responses in vivo. Treatment of endothelial cells with FVIIa suppressed tumor necrosis factor α (TNF-α)- and LPS-induced expression of cellular adhesion molecules and adherence of monocytes to endothelial cells. Inhibition of EPCR or protease-activated receptor 1 (PAR1) by either specific antibodies or small interfering RNA abolished the FVIIa-induced suppression of TNF-α- and LPS-induced expression of cellular adhesion molecules and interleukin-6. β-Arrestin-1 silencing blocked the FVIIa-induced anti-inflammatory effect in endothelial cells. In vivo studies showed that FVIIa treatment markedly suppressed LPS-induced inflammatory cytokines and infiltration of innate immune cells into the lung in wild-type and EPCR-overexpressing mice, but not in EPCR-deficient mice. Mechanistic studies revealed that FVIIa treatment inhibited TNF-α-induced ERK1/2, p38 MAPK, JNK, NF-κB, and C-Jun activation indicating that FVIIa-mediated signaling blocks an upstream signaling event in TNFα-induced signaling cascade. FVIIa treatment impaired the recruitment of TNF-receptor-associated factor 2 into the TNF receptor 1 signaling complex. Overall, our present data provide convincing evidence that FVIIa binding to EPCR elicits anti-inflammatory signaling via a PAR1- and β-arrestin-1 dependent pathway. The present study suggests new therapeutic potentials for FVIIa, which is currently in clinical use for treating bleeding disorders. |
| Author | Wang, Jue Kondreddy, Vijay Pendurthi, Usha R Keshava, Shiva Rao, L Vijaya Mohan Esmon, Charles T |
| Author_xml | – sequence: 1 givenname: Vijay surname: Kondreddy fullname: Kondreddy, Vijay organization: Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, TX; and – sequence: 2 givenname: Jue surname: Wang fullname: Wang, Jue organization: Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, TX; and – sequence: 3 givenname: Shiva surname: Keshava fullname: Keshava, Shiva organization: Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, TX; and – sequence: 4 givenname: Charles T surname: Esmon fullname: Esmon, Charles T organization: Coagulation Biology Laboratory, Oklahoma Medical Research Foundation, Oklahoma City, OK – sequence: 5 givenname: L Vijaya Mohan orcidid: 0000-0003-2099-0585 surname: Rao fullname: Rao, L Vijaya Mohan organization: Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, TX; and – sequence: 6 givenname: Usha R orcidid: 0000-0002-7138-9362 surname: Pendurthi fullname: Pendurthi, Usha R organization: Department of Cellular and Molecular Biology, The University of Texas Health Science Center at Tyler, Tyler, TX; and |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/29669778$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNj11LwzAYhYNM3If-A5FcehN9kzZNcjnGpoOBY6i35W2TjkibzqYV9u83cIJX54HzcOBMySi0wRFyz-GJcy2ei7ptLRPAFePANE-kUFdkwqXQDEDA6B-PyTTGLwCeJkLekLEwWWaU0hMyX2HZtx39XK-R-mCH0kWKoffMh6rGpsFze6TR7wPWPuzpj0e63C52Z8nS7XzHb8l1hXV0d5eckY_V8n3xyjZvL-vFfMNKKUzPEskhq1ChKGTqMIMKCqWdNlZpcMZBwqsEbYKFzUqly5RbqFLHTVUqixzFjDz-7h669ntwsc8bH0tX1xhcO8RcgFDSaJPCWX24qEPROJsfOt9gd8z_bosT-4VbwQ |
| CitedBy_id | crossref_primary_10_1016_j_jtha_2023_08_025 crossref_primary_10_3389_fvets_2022_890043 crossref_primary_10_1111_os_14172 crossref_primary_10_1186_s12964_025_02066_6 crossref_primary_10_3390_cancers11010051 crossref_primary_10_3390_jcm13072030 crossref_primary_10_1002_rth2_12563 crossref_primary_10_1038_s41467_022_28729_3 crossref_primary_10_1182_blood_2021012358 crossref_primary_10_1016_j_clim_2023_109745 crossref_primary_10_1016_j_ijbiomac_2024_137235 crossref_primary_10_1111_jth_14643 crossref_primary_10_1161_ATVBAHA_121_316153 crossref_primary_10_3390_cancers11081103 crossref_primary_10_1016_j_jtha_2024_07_022 crossref_primary_10_1097_MBC_0000000000001373 crossref_primary_10_1126_science_abg6449 crossref_primary_10_1182_blood_2019003824 crossref_primary_10_1182_bloodadvances_2018027219 crossref_primary_10_1186_s12959_019_0194_8 crossref_primary_10_1186_s12964_024_01547_4 crossref_primary_10_2183_pjab_101_006 crossref_primary_10_3389_fcvm_2022_867646 crossref_primary_10_1016_j_intimp_2025_114218 crossref_primary_10_1038_s41598_020_77502_3 crossref_primary_10_1097_SHK_0000000000001845 crossref_primary_10_1128_msphere_00451_23 crossref_primary_10_1161_ATVBAHA_123_320185 crossref_primary_10_1093_cvr_cvaa263 crossref_primary_10_1186_s12951_022_01681_6 crossref_primary_10_1016_j_jtha_2023_10_021 crossref_primary_10_1186_s12916_025_04043_9 crossref_primary_10_1002_ptr_6676 crossref_primary_10_1182_blood_2020008417 crossref_primary_10_1093_rheumatology_keaa701 crossref_primary_10_1111_jth_15221 crossref_primary_10_3390_cells14070485 crossref_primary_10_3390_ijms20071762 crossref_primary_10_1055_a_2374_2903 crossref_primary_10_1097_MBC_0000000000000775 crossref_primary_10_1161_ATVBAHA_120_314244 crossref_primary_10_1016_j_lfs_2023_122061 |
| ContentType | Journal Article |
| Copyright | 2018 by The American Society of Hematology. |
| Copyright_xml | – notice: 2018 by The American Society of Hematology. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1182/blood-2017-10-813527 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology Anatomy & Physiology |
| EISSN | 1528-0020 |
| ExternalDocumentID | 29669778 |
| Genre | Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NHLBI NIH HHS grantid: UM1 HL120877 – fundername: NHLBI NIH HHS grantid: R01 HL107483 |
| GroupedDBID | --- -~X .55 0R~ 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6J9 AAEDW AALRI AAXUO ABOCM ACGFO ADBBV ADVLN AENEX AFETI AFOSN AITUG AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD EX3 F5P FDB FRP GS5 GX1 H13 IH2 K-O KQ8 L7B LSO MJL N9A NPM OK1 P2P R.V RHF RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV 7X8 ACVFH ADCNI AEUPX AFPUW AIGII AKBMS AKYEP EFKBS |
| ID | FETCH-LOGICAL-c529t-35106fa7a2b54ea60f0b78e89d780e9e031f3ad3abd6c78c41d0f4e19fc7da1a2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 47 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000433142600015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1528-0020 |
| IngestDate | Sun Sep 28 00:07:32 EDT 2025 Wed Feb 19 02:30:39 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 21 |
| Language | English |
| License | 2018 by The American Society of Hematology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c529t-35106fa7a2b54ea60f0b78e89d780e9e031f3ad3abd6c78c41d0f4e19fc7da1a2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-2099-0585 0000-0002-7138-9362 |
| OpenAccessLink | https://dx.doi.org/10.1182/blood-2017-10-813527 |
| PMID | 29669778 |
| PQID | 2027598940 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2027598940 pubmed_primary_29669778 |
| PublicationCentury | 2000 |
| PublicationDate | 2018-05-24 20180524 |
| PublicationDateYYYYMMDD | 2018-05-24 |
| PublicationDate_xml | – month: 05 year: 2018 text: 2018-05-24 day: 24 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Blood |
| PublicationTitleAlternate | Blood |
| PublicationYear | 2018 |
| SSID | ssj0014325 |
| Score | 2.4677646 |
| Snippet | Recent studies show that endothelial cell protein C receptor (EPCR) interacts with diverse ligands, in addition to its known ligands protein C and activated... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2379 |
| SubjectTerms | Animals beta-Arrestins - metabolism Biomarkers Endothelial Protein C Receptor - genetics Endothelial Protein C Receptor - metabolism Factor VIIa - metabolism Gene Expression Regulation Human Umbilical Vein Endothelial Cells - metabolism Humans Inflammation - genetics Inflammation - metabolism Inflammation Mediators - metabolism Lipopolysaccharides - adverse effects Lipopolysaccharides - immunology Mice Receptor, PAR-1 - genetics Receptor, PAR-1 - metabolism Signal Transduction Tumor Necrosis Factor-alpha - metabolism |
| Title | Factor VIIa induces anti-inflammatory signaling via EPCR and PAR1 |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/29669778 https://www.proquest.com/docview/2027598940 |
| Volume | 131 |
| WOSCitedRecordID | wos000433142600015&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1bS8MwFD541xcv834jgvhWTNs0SZ9kjg0FN8ZQ2dtIkxT2YDfdHPjvPUlbfBIEX0ofWmhzTk6-L-fkfADXXGqWcqYCEZosYEmoA5lphvMqoYZLxWPfTOf1SfR6cjhM-9WG26wqq6xjog_UZqLdHrkn6YnrFk7vpu-BU41y2dVKQmMZVmOEMs6rxfAni8BiL7qKS5QMHC6qjs4hpL4ty8IjF6MxEMkQcYj4HWT6xaaz89_P3IXtCmaSZukXe7BkiwbsNwuk2G9f5Ib4wk-_o96A9fv6brNVy781YKNbZd33odnxojzk9fFREeTw6A0zghYZB-ie6FFvPlNPXCmIcqfbyWKsSLvfGuBDhvSbg_AAXjrt59ZDUEkvBDqJ0rmr76c8V0JFWcKs4jSnmZBWpkZIalOLoSCPlYlVZrgWaO_Q0JzZMM21MCpU0SGsFJPCHgNhGsNplHOL3I4xoZVGWmwQNaWUUx0nJ3BVj-QIf9HlK1RhJ5-z0c9YnsBRaY7RtOzBMYqQpiF0lad_ePsMttDQ0uX8I3YOqzlObHsBa3oxH88-Lr3P4LXX734DO1bH9w |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Factor+VIIa+induces+anti-inflammatory+signaling+via+EPCR+and+PAR1&rft.jtitle=Blood&rft.au=Kondreddy%2C+Vijay&rft.au=Wang%2C+Jue&rft.au=Keshava%2C+Shiva&rft.au=Esmon%2C+Charles+T&rft.date=2018-05-24&rft.issn=1528-0020&rft.eissn=1528-0020&rft.volume=131&rft.issue=21&rft.spage=2379&rft_id=info:doi/10.1182%2Fblood-2017-10-813527&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-0020&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-0020&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-0020&client=summon |